You are now leaving Celsius Therapeutics to visit a third-party website, which is solely responsible for all content and privacy policies.
Vice President, Oncology
Gromek Smolen has nearly 20 years of oncology experience and a proven record of building high-performing teams, discovering new drug targets and leading drug discovery projects in the context of novel biology. At Celsius, he leads target identification/validation, early drug discovery, and clinical partnerships across the company’s oncology portfolio.
Gromek joined Celsius in 2018 from Agios Pharmaceuticals, where he led the cancer exploratory portfolio of target identification and validation projects. He also shaped Agios’ pipeline of targets in metabolic immuno-oncology and rare genetic diseases.
Gromek obtained his Ph.D. from Johns Hopkins University and completed his postdoctoral training in the lab of Dr. Daniel Haber at Massachusetts General Hospital/Harvard Medical School.